Pub Date : 2024-03-11DOI: 10.1007/s13410-024-01328-2
Jessica Castro de Vasconcelos, Yeelen Ballesteros Atala, Denise Engelbrecht Zantut-Wittmann, Maria Cândida Ribeiro Parisi
Objective
This study aimed to assess the presence and characteristics of cardiovascular autonomic neuropathy (CAN) in people with type 2 diabetes with and without Charcot neuroarthropathy (CN).
Background
Diabetes can affect nerves in many ways beyond sensitive neuropathy.
Methods
A cross-sectional study was carried out in people with diabetes and CN who were matched for sex and age with two groups of people with diabetes without CN. All subjects underwent CAN assessment with seven tests (four Ewing tests and three bands of spectral analysis), and a severity score was constructed using these seven tests (each altered test equivalent to 1 point).
Results
Of the 69 people evaluated, 49 (71%) had incipient or installed CAN. A total of 95.2% of people with Charcot neuroarthropathy had incipient or installed CAN. There was a higher prevalence of dyslipidemia among people with installed autonomic neuropathy than among those with incipient CAN or without CAN. Thirty-four (69%) people with CAN had increased urinary albumin excretion. The severity score, constructed from the seven tests used for the diagnosis of CAN, revealed a greater number of altered tests and higher scores among people with CN when compared to the other participants, indicating greater severity of the condition.
Conclusions
There is a high prevalence of CAN in people with type 2 diabetes followed in a tertiary health service and the use of severity score may enable to differentiate people with or without CN. We suggest that this score could be used as a new tool in caring for people with diabetes to identify the most severe CAN.
本研究旨在评估伴有或不伴有 Charcot 神经性关节病(CN)的 2 型糖尿病患者中是否存在心血管自主神经病变(CAN)及其特征。背景糖尿病会以多种方式影响神经,而不仅仅是敏感性神经病变。方法对伴有 CN 的糖尿病患者和两组不伴有 CN 的糖尿病患者进行横断面研究,这两组患者的性别和年龄相匹配。所有受试者都通过七项测试(四项尤因测试和三段频谱分析)对 CAN 进行了评估,并通过这七项测试得出了严重程度评分(每项改变的测试相当于 1 分)。共有 95.2% 的夏科神经关节病患者患有初期或已安装的 CAN。在患有自律神经病的患者中,血脂异常的发病率要高于初发或未安装 CAN 的患者。34名(69%)自律神经病患者的尿白蛋白排泄量增加。根据用于诊断 CAN 的七项测试得出的严重程度评分显示,与其他参与者相比,CN 患者的测试项目发生变化的次数更多,得分更高,表明病情更为严重。我们建议在护理糖尿病患者时将该评分作为一种新工具,以识别最严重的 CAN。
{"title":"Cardiovascular autonomic neuropathy and charcot neuroarthropathy in type 2 diabetes: adding a new severity classification score","authors":"Jessica Castro de Vasconcelos, Yeelen Ballesteros Atala, Denise Engelbrecht Zantut-Wittmann, Maria Cândida Ribeiro Parisi","doi":"10.1007/s13410-024-01328-2","DOIUrl":"https://doi.org/10.1007/s13410-024-01328-2","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>This study aimed to assess the presence and characteristics of cardiovascular autonomic neuropathy (CAN) in people with type 2 diabetes with and without Charcot neuroarthropathy (CN).</p><h3 data-test=\"abstract-sub-heading\">Background</h3><p>Diabetes can affect nerves in many ways beyond sensitive neuropathy.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A cross-sectional study was carried out in people with diabetes and CN who were matched for sex and age with two groups of people with diabetes without CN. All subjects underwent CAN assessment with seven tests (four Ewing tests and three bands of spectral analysis), and a severity score was constructed using these seven tests (each altered test equivalent to 1 point).</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Of the 69 people evaluated, 49 (71%) had incipient or installed CAN. A total of 95.2% of people with Charcot neuroarthropathy had incipient or installed CAN. There was a higher prevalence of dyslipidemia among people with installed autonomic neuropathy than among those with incipient CAN or without CAN. Thirty-four (69%) people with CAN had increased urinary albumin excretion. The severity score, constructed from the seven tests used for the diagnosis of CAN, revealed a greater number of altered tests and higher scores among people with CN when compared to the other participants, indicating greater severity of the condition.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>There is a high prevalence of CAN in people with type 2 diabetes followed in a tertiary health service and the use of severity score may enable to differentiate people with or without CN. We suggest that this score could be used as a new tool in caring for people with diabetes to identify the most severe CAN.</p>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140097519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-09DOI: 10.1007/s13410-024-01326-4
Mahak Golani, Sanjay Pandit, Sumeet Singla
Objective
To determine the proportion of patients of type 2 Diabetes taking oral antidiabetics with self reported hypoglycemia and its causes.
Background
Hypoglycemia, an acute complication of diabetes mellitus is not only responsible for recurrent morbidity but also can lead to permanent brain damage or fatality if not recognized and treated in time. Also, hypoglycemia prevents achieving glycemic targets in diabetic patients.
Methods
Cross-sectional observation study of 70 patients of type 2 diabetes on oral anti-diabetics was conducted at Lok Nayak Hospital to determine the proportion of patients with self reported hypoglycemia and also to find out the various causes of hypoglycemia by subjecting them to a structured questionnaire. Hypoglycemia was considered when patient experienced at least one symptom, at least 2–3 times in last one month and symptom(s) were relieved by consuming sugar/meal.
Results
38.6% of the study subjects had hypoglycemia, out of which 92.59% patients had symptomatic hypoglycemia. Out of the patients experiencing hypoglycemia, 32% had severe episodes, 12% visited the hospital and 48% had more than 5 episodes per month. Dizziness was the commonest reported symptom (64%), followed by palpitations (52%). Attributed causes of hypoglycemia were missing meal (64%), drugs other than oral anti-diabetics (44%), sulfonylureas (44.2% in patients taking vs. 26.9% in patients not taking sulfonylurea), comorbidities (41% with vs. 22.4% without comorbidities) and lower socioeconomic status. One-third of patients experiencing were checking blood glucose levels during the symptoms. Highest prevalence of hypoglycemia was seen with HbA1c < 6.5% (p-value 0.04 when compared with subjects with HbA1c ≥ 6.5%), followed by ≥ 8% and least in 6.5–7.9%.
Conclusions
Lower prevalence of hypoglycemia in our study compared to other similar studies could be because of non-inclusion of patients on insulin in our study. High prevalence of multiple episodes justify the fact that hypoglycemia begets hypoglycemia. Hypoglycemia progressively increased as socioeconomic status changed from higher to lower, possibly due to non-availability of glucometer and lack of information. U-shaped correlation of hypoglycemic events was found with HbA1c levels.
{"title":"Self reported hypoglycemia in patients with type 2 diabetes mellitus taking oral anti-diabetics","authors":"Mahak Golani, Sanjay Pandit, Sumeet Singla","doi":"10.1007/s13410-024-01326-4","DOIUrl":"https://doi.org/10.1007/s13410-024-01326-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>To determine the proportion of patients of type 2 Diabetes taking oral antidiabetics with self reported hypoglycemia and its causes.</p><h3 data-test=\"abstract-sub-heading\">Background</h3><p>Hypoglycemia, an acute complication of diabetes mellitus is not only responsible for recurrent morbidity but also can lead to permanent brain damage or fatality if not recognized and treated in time. Also, hypoglycemia prevents achieving glycemic targets in diabetic patients.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Cross-sectional observation study of 70 patients of type 2 diabetes on oral anti-diabetics was conducted at Lok Nayak Hospital to determine the proportion of patients with self reported hypoglycemia and also to find out the various causes of hypoglycemia by subjecting them to a structured questionnaire. Hypoglycemia was considered when patient experienced at least one symptom, at least 2–3 times in last one month and symptom(s) were relieved by consuming sugar/meal.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>38.6% of the study subjects had hypoglycemia, out of which 92.59% patients had symptomatic hypoglycemia. Out of the patients experiencing hypoglycemia, 32% had severe episodes, 12% visited the hospital and 48% had more than 5 episodes per month. Dizziness was the commonest reported symptom (64%), followed by palpitations (52%). Attributed causes of hypoglycemia were missing meal (64%), drugs other than oral anti-diabetics (44%), sulfonylureas (44.2% in patients taking vs. 26.9% in patients not taking sulfonylurea), comorbidities (41% with vs. 22.4% without comorbidities) and lower socioeconomic status. One-third of patients experiencing were checking blood glucose levels during the symptoms. Highest prevalence of hypoglycemia was seen with HbA<sub>1c</sub> < 6.5% (<i>p</i>-value 0.04 when compared with subjects with HbA<sub>1c</sub> ≥ 6.5%), followed by ≥ 8% and least in 6.5–7.9%.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Lower prevalence of hypoglycemia in our study compared to other similar studies could be because of non-inclusion of patients on insulin in our study. High prevalence of multiple episodes justify the fact that hypoglycemia begets hypoglycemia. Hypoglycemia progressively increased as socioeconomic status changed from higher to lower, possibly due to non-availability of glucometer and lack of information. U-shaped correlation of hypoglycemic events was found with HbA<sub>1c</sub> levels.</p>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140097603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-07DOI: 10.1007/s13410-024-01322-8
Miguel Altuve, Erika Severeyn
Objective
Plasma glucose and insulin concentrations are clinical markers used to diagnose metabolic diseases, particularly prediabetes and diabetes. In this paper, we conducted a cluster analysis using plasma glucose and insulin data collected during both fasting and 2-h postprandial periods.
Methods
Different clustering experiments were performed by changing the attributes, from one (fasting glucose) to four (fasting and postprandial glucose and insulin) attributes input to a k-means clustering algorithm. Based on the elbow and silhouette methods, three clusters were chosen to perform the clustering experiments. The Pearson correlation coefficient was utilized to evaluate the association between the levels of glucose and insulin within each created cluster.
Results
Results show that one cluster comprised individuals with prediabetes, another cluster consisted of individuals with diabetes, while subjects without prediabetes and diabetes were assigned to a separate cluster. Despite not being used as an attribute, we observed varying age ranges among subjects in the three clusters. Furthermore, significant correlations were found between fasting and postprandial insulin levels, as well as between fasting and postprandial glucose levels, suggesting a consistent relationship between these variables, and highlighting their interdependence in the context of glucose metabolism.
Conclusion
The clustering analysis successfully differentiated individuals into distinct clusters based on their metabolic conditions, confirming that the approach effectively captured the underlying patterns in the plasma glucose and insulin data. Furthermore, despite not being a considered attribute, the varying age ranges observed within the clusters indicate that age may play a role in the development and progression of diabetes. Additionally, the fasting and postprandial associations in insulin and glucose levels exhibited greater strength in the cluster encompassing individuals with diabetes, where insulin production or action is compromised.
{"title":"Cluster analysis based on fasting and postprandial plasma glucose and insulin concentrations","authors":"Miguel Altuve, Erika Severeyn","doi":"10.1007/s13410-024-01322-8","DOIUrl":"https://doi.org/10.1007/s13410-024-01322-8","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>Plasma glucose and insulin concentrations are clinical markers used to diagnose metabolic diseases, particularly prediabetes and diabetes. In this paper, we conducted a cluster analysis using plasma glucose and insulin data collected during both fasting and 2-h postprandial periods.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Different clustering experiments were performed by changing the attributes, from one (fasting glucose) to four (fasting and postprandial glucose and insulin) attributes input to a k-means clustering algorithm. Based on the elbow and silhouette methods, three clusters were chosen to perform the clustering experiments. The Pearson correlation coefficient was utilized to evaluate the association between the levels of glucose and insulin within each created cluster.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Results show that one cluster comprised individuals with prediabetes, another cluster consisted of individuals with diabetes, while subjects without prediabetes and diabetes were assigned to a separate cluster. Despite not being used as an attribute, we observed varying age ranges among subjects in the three clusters. Furthermore, significant correlations were found between fasting and postprandial insulin levels, as well as between fasting and postprandial glucose levels, suggesting a consistent relationship between these variables, and highlighting their interdependence in the context of glucose metabolism.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The clustering analysis successfully differentiated individuals into distinct clusters based on their metabolic conditions, confirming that the approach effectively captured the underlying patterns in the plasma glucose and insulin data. Furthermore, despite not being a considered attribute, the varying age ranges observed within the clusters indicate that age may play a role in the development and progression of diabetes. Additionally, the fasting and postprandial associations in insulin and glucose levels exhibited greater strength in the cluster encompassing individuals with diabetes, where insulin production or action is compromised.</p>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140054557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-07DOI: 10.1007/s13410-024-01325-5
Cem Yesiloglu, Canan Emiroglu, Cenk Aypak
Objective
Cardiovascular diseases (CVD) are the most common, deadly, noncommunicable disease group globally. This study aims to investigate the relationship between Systematic Coronary Risk Evaluation 2 (SCORE2) scores, which indicate the risk of future CVD in patients without known CVD and diabetes mellitus (DM) diagnoses, and HbA1c values.
Methods
In our retrospective cross-sectional study, patients under 40 years of age and over 69 years, those with a history of any CVD, those with a history of type 1 or type 2 DM, individuals with known anemia, patients using antihyperlipidemic or antidiabetic medications, and those with HbA1c levels of 6.5 and above were excluded. The relationship between the SCORE2 risk scores and related parameters was investigated among the included 249 patients.
Results
Among a total of 249 patients, with a mean age of 51.9 ± 7.5 years, 137 (55.0%) were male. Positive correlations were found between the SCORE2 (%) value of the patients and hemoglobin (rho = 0.222; p < 0.001), red blood cell (rho = 0.207; p = 0.001), hematocrit (rho = 0.267; p < 0.001), white blood cell (rho = 0.147; p = 0.021), triglyceride (rho = 0.247; p = 0.004), glucose (rho = 0.244; p < 0.001), HbA1c (rho = 0.208; p < 0.001), waist circumference (rho = 0.204; p = 0.001), and Visceral Adiposity Index (VAI) (rho = 0.145; p = 0.023) values.
Conclusion
A significant relationship was found between HbA1c and the current CVD risk score, SCORE2, in our patient group without DM. Our study is the first to examine this relationship in the literature. While no relationship was found between SCORE2 and body mass index (BMI), a significant relationship was found with the VAI. This indicates that CVD risk is more associated with visceral fat accumulation than total weight. Evaluating patients with normal BMI based on VAI will be beneficial in demonstrating CVD risk.
{"title":"The relationship between glycated hemoglobin (HbA1c), hematocrit, mean platelet volume, total white blood cell counts, Visceral Adiposity Index, and Systematic Coronary Risk Evaluation 2 (SCORE2) in patients without diabetes","authors":"Cem Yesiloglu, Canan Emiroglu, Cenk Aypak","doi":"10.1007/s13410-024-01325-5","DOIUrl":"https://doi.org/10.1007/s13410-024-01325-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>Cardiovascular diseases (CVD) are the most common, deadly, noncommunicable disease group globally. This study aims to investigate the relationship between Systematic Coronary Risk Evaluation 2 (SCORE2) scores, which indicate the risk of future CVD in patients without known CVD and diabetes mellitus (DM) diagnoses, and HbA1c values.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>In our retrospective cross-sectional study, patients under 40 years of age and over 69 years, those with a history of any CVD, those with a history of type 1 or type 2 DM, individuals with known anemia, patients using antihyperlipidemic or antidiabetic medications, and those with HbA1c levels of 6.5 and above were excluded. The relationship between the SCORE2 risk scores and related parameters was investigated among the included 249 patients.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Among a total of 249 patients, with a mean age of 51.9 ± 7.5 years, 137 (55.0%) were male. Positive correlations were found between the SCORE2 (%) value of the patients and hemoglobin (rho = 0.222; <i>p</i> < 0.001), red blood cell (rho = 0.207; <i>p</i> = 0.001), hematocrit (rho = 0.267; <i>p</i> < 0.001), white blood cell (rho = 0.147; <i>p</i> = 0.021), triglyceride (rho = 0.247; <i>p</i> = 0.004), glucose (rho = 0.244; <i>p</i> < 0.001), HbA1c (rho = 0.208; <i>p</i> < 0.001), waist circumference (rho = 0.204; <i>p</i> = 0.001), and Visceral Adiposity Index (VAI) (rho = 0.145; <i>p</i> = 0.023) values.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>A significant relationship was found between HbA1c and the current CVD risk score, SCORE2, in our patient group without DM. Our study is the first to examine this relationship in the literature. While no relationship was found between SCORE2 and body mass index (BMI), a significant relationship was found with the VAI. This indicates that CVD risk is more associated with visceral fat accumulation than total weight. Evaluating patients with normal BMI based on VAI will be beneficial in demonstrating CVD risk.</p>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140054554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-02DOI: 10.1007/s13410-024-01324-6
Abstract
Objective
Rosuvastatin is a drug used for decreasing the risk of cardiovascular complications in type 2 diabetes mellitus (T2DM) patients. It is hypothesized that fetuin-A encourages lipid-induced insulin resistance and sortilin may increase the risk of atherosclerotic-related disorders. The aim of this study is to investigate the safety and efficacy of rosuvastatin co-treatment in T2DM patients and its effect on levels of sortilin and fetuin-A.
Methods
Seventy T2DM patients treated with glimepiride and metformin were randomly assigned to either co-treated with rosuvastatin 10 mg tablets (rosuvastatin group, n = 40), or placebo (placebo group, n = 30) daily for 3 months in a parallel, double-blind randomized controlled trial. Blood was collected for biochemical analysis. Serum sortilin and fetuin-A levels, glycemic and lipid profiles were measured before and 3 months after intervention.
Results
Fasting blood glucose (FBG, mg/dl) significantly decreased in placebo and rousvastatin groups from (104 ± 7.24 to 96.67 ± 7.14 vs 102.8 ± 6.43 to 93.0 ± 4.71), respectively, compared with baseline (p < 0.05). BMI and HbA1c decreased in placebo vs rosuvastatin group (29.20 ± 3.18 to 28.10 ± 3.08, p=0.08 vs 28.67 ± 3.56 to 27.66 ± 3.16, p = 0.27), and (6.59 ± 0.27 to 6.36 ± 0.27 vs 6.56 ± 0.26 to 6.29 ± 0.25), respectively, compared with baseline (p ≤ 0.001) with no significance difference between both groups (p = 0.58 and p = 0.25, respectively). Sortilin and fetuin-A levels significantly decreased in rosuvastatin vs placebo group from (1.77 ± 0.41 to 0.64 ± 0.37 vs 1.70 ± 0.36 to 1.65 ± 0.36) and from (295.33 ± 52.04 to 179.75 ± 60.22 vs 307.22 ± 50.11 to 288.94 ± 49.53), respectively, compared with baseline with significance difference between both groups (p < 0.001) compared with placebo. Significant positive correlation was found between sortilin with fetuin-A, low-density lipoprotein (LDL-C), and atherogenic index (p < 0.001). Significant positive correlation was observed between fetuin-A with FBG (p < 0.05) and atherogenic index (p < 0.001).
Conclusion
Rosuvastatin co-treatment in T2DM patients improves glycemic control and aids in decreasing the atherogenic biomarkers sortilin and fetuin-A levels, so it can be considered tolerable and efficient in improving lipid profile and atherogenic index.
Trial registration
ClinicalTrials.gov identifier (NCT number): NCT03907423, (The registration date: April 9, 2019). https://clinicaltrials.gov/ct2/show/NCT03907423.
{"title":"Effect of rosuvastatin on sortilin and fetuin-A in type 2 diabetic patients: a randomized controlled trial","authors":"","doi":"10.1007/s13410-024-01324-6","DOIUrl":"https://doi.org/10.1007/s13410-024-01324-6","url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Objective</h3> <p>Rosuvastatin is a drug used for decreasing the risk of cardiovascular complications in type 2 diabetes mellitus (T2DM) patients. It is hypothesized that fetuin-A encourages lipid-induced insulin resistance and sortilin may increase the risk of atherosclerotic-related disorders. The aim of this study is to investigate the safety and efficacy of rosuvastatin co-treatment in T2DM patients and its effect on levels of sortilin and fetuin-A.</p> </span> <span> <h3>Methods</h3> <p>Seventy T2DM patients treated with glimepiride and metformin were randomly assigned to either co-treated with rosuvastatin 10 mg tablets (rosuvastatin group, <em>n</em> = 40), or placebo (placebo group, <em>n</em> = 30) daily for 3 months in a parallel, double-blind randomized controlled trial. Blood was collected for biochemical analysis. Serum sortilin and fetuin-A levels, glycemic and lipid profiles were measured before and 3 months after intervention.</p> </span> <span> <h3>Results</h3> <p>Fasting blood glucose (FBG, mg/dl) significantly decreased in placebo and rousvastatin groups from (104 ± 7.24 to 96.67 ± 7.14 vs 102.8 ± 6.43 to 93.0 ± 4.71), respectively, compared with baseline (<em>p</em> < 0.05). BMI and HbA1c decreased in placebo vs rosuvastatin group (29.20 ± 3.18 to 28.10 ± 3.08, p=0.08 vs 28.67 ± 3.56 to 27.66 ± 3.16, <em>p </em>= 0.27), and (6.59 ± 0.27 to 6.36 ± 0.27 vs 6.56 ± 0.26 to 6.29 ± 0.25), respectively, compared with baseline (<em>p</em> ≤ 0.001) with no significance difference between both groups (<em>p</em> = 0.58 and <em>p </em>= 0.25, respectively). Sortilin and fetuin-A levels significantly decreased in rosuvastatin vs placebo group from (1.77 ± 0.41 to 0.64 ± 0.37 vs 1.70 ± 0.36 to 1.65 ± 0.36) and from (295.33 ± 52.04 to 179.75 ± 60.22 vs 307.22 ± 50.11 to 288.94 ± 49.53), respectively, compared with baseline with significance difference between both groups (<em>p</em> < 0.001) compared with placebo. Significant positive correlation was found between sortilin with fetuin-A, low-density lipoprotein (LDL-C), and atherogenic index (<em>p</em> < 0.001). Significant positive correlation was observed between fetuin-A with FBG (<em>p</em> < 0.05) and atherogenic index (<em>p</em> < 0.001).</p> </span> <span> <h3>Conclusion</h3> <p>Rosuvastatin co-treatment in T2DM patients improves glycemic control and aids in decreasing the atherogenic biomarkers sortilin and fetuin-A levels, so it can be considered tolerable and efficient in improving lipid profile and atherogenic index.</p> </span> <span> <h3>Trial registration</h3> <p>ClinicalTrials.gov identifier (NCT number): <strong>NCT03907423, (The registration date: April 9, 2019). </strong>https://clinicaltrials.gov/ct2/show/NCT03907423<strong>.</strong></p> </span>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140017267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-24DOI: 10.1007/s13410-024-01323-7
Sachdev Meenakshi, Viswanathan Mohan
Background
This commentary explores the landscape of non-nutritive sweeteners, further delves into the historical trajectory and the contemporary surge in the consumption of non-nutritive sweeteners (NNS), along with the accompanying controversies concerning their safety.
Objective
The aim is to provide a comprehensive understanding of the influences of NNS, drawn from global studies and diverse perspectives.
Methods
The commentary synthesizes findings from global studies, notably the NutriNet-Santé cohort, exploring associations between specific NNS and health consequences such as cerebrovascular events and malignancies. Additionally, it examines the research on consequences of NNS on gut microbiota and explores concerns linked to gestational diabetes, fetal exposure, and health of the offspring.
Results
While caution is advised during pregnancy and fetal development due to potential risks, NNS show promise in weight management and short-term dietary goals when used cautiously in lower amounts. The commentary underscores the necessity for inclusive, long-term studies to guide evidence-driven policies and guidelines.
Conclusion
While the article underscores the complexities and debates surrounding non-nutritive sweeteners (NNS), it also sheds light on the positive aspects. In the Indian context, where the intake of sweeteners is relatively low and mainly limited to beverages (tea or coffee), NNS appear to be safe, but prudent use is advocated. The article emphasizes the value of public education on NNS usage and concludes that, overall, NNS are reasonably safe when consumed in moderation. Continued research is needed to elucidate their intricate effects on health and impact on global health outcomes.
Implications
The article concludes with clear guidelines for using NNS in India, highlighting the need for informed decision-making and ongoing research to elucidate their broader health consequences.
{"title":"Decoding the mystery of non-nutritive sweeteners","authors":"Sachdev Meenakshi, Viswanathan Mohan","doi":"10.1007/s13410-024-01323-7","DOIUrl":"https://doi.org/10.1007/s13410-024-01323-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>This commentary explores the landscape of non-nutritive sweeteners, further delves into the historical trajectory and the contemporary surge in the consumption of non-nutritive sweeteners (NNS), along with the accompanying controversies concerning their safety.</p><h3 data-test=\"abstract-sub-heading\">Objective</h3><p>The aim is to provide a comprehensive understanding of the influences of NNS, drawn from global studies and diverse perspectives.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The commentary synthesizes findings from global studies, notably the NutriNet-Santé cohort, exploring associations between specific NNS and health consequences such as cerebrovascular events and malignancies. Additionally, it examines the research on consequences of NNS on gut microbiota and explores concerns linked to gestational diabetes, fetal exposure, and health of the offspring.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>While caution is advised during pregnancy and fetal development due to potential risks, NNS show promise in weight management and short-term dietary goals when used cautiously in lower amounts. The commentary underscores the necessity for inclusive, long-term studies to guide evidence-driven policies and guidelines.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>While the article underscores the complexities and debates surrounding non-nutritive sweeteners (NNS), it also sheds light on the positive aspects. In the Indian context, where the intake of sweeteners is relatively low and mainly limited to beverages (tea or coffee), NNS appear to be safe, but prudent use is advocated. The article emphasizes the value of public education on NNS usage and concludes that, overall, NNS are reasonably safe when consumed in moderation. Continued research is needed to elucidate their intricate effects on health and impact on global health outcomes.</p><h3 data-test=\"abstract-sub-heading\">Implications</h3><p>The article concludes with clear guidelines for using NNS in India, highlighting the need for informed decision-making and ongoing research to elucidate their broader health consequences.</p>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139954392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22DOI: 10.1007/s13410-024-01320-w
Veysel Ürekli, Egemen Tural, Akın Dayan
Objective
Poor sugar regulation heightens the risk of complications linked to type 2 diabetes mellitus, while the adoption of effective diabetes self-management strategies has been shown to mitigate these risks. The objective of the study was to investigate the risk factors for diabetic foot by evaluating diabetes self-management using the Diabetes Self-Management Scale in patients with type 2 diabetes mellitus with and without diabetic foot.
Methods
The study is a single-centre, prospective, cross-sectional study conducted between August 29, 2022 and November 29, 2022. A total of 133 patients who presented to the diabetes and diabetic foot outpatient clinic were selected using a simple random sampling method. In order to make the evaluation, the sociodemographic form and Diabetes Self-Management Scale has been used. Potential risk factors associated with the presence of diabetic foot were examined using multivariate logistic regression analysis. A significance level of p < 0.05 was considered statistically significant.
Results
The mean age of the patients was 60.35 years and 45.1% (60) of them were female. According to the results of the multivariate logistic regression analysis, having more than 12 years of education, receiving diabetes education, and having higher Diabetes Self-Management Scale total scores negatively predicted the presence of diabetic foot. On the other hand, the duration of diabetes, systolic blood pressure, and HbA1c levels positively predicted the presence of diabetic foot.
Conclusion
Effective diabetes self-management plays a crucial role in improving diabetes complications. Care should be taken regarding diabetic foot in patients who have difficulties in effective diabetes self-management, as well as those with high systolic blood pressure, high HbA1c levels, shorter total education duration, and longer duration of diabetes.
{"title":"Examining risk factors for diabetic foot: assessing diabetes self-management in type 2 diabetes patients","authors":"Veysel Ürekli, Egemen Tural, Akın Dayan","doi":"10.1007/s13410-024-01320-w","DOIUrl":"https://doi.org/10.1007/s13410-024-01320-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>Poor sugar regulation heightens the risk of complications linked to type 2 diabetes mellitus, while the adoption of effective diabetes self-management strategies has been shown to mitigate these risks. The objective of the study was to investigate the risk factors for diabetic foot by evaluating diabetes self-management using the Diabetes Self-Management Scale in patients with type 2 diabetes mellitus with and without diabetic foot.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The study is a single-centre, prospective, cross-sectional study conducted between August 29, 2022 and November 29, 2022. A total of 133 patients who presented to the diabetes and diabetic foot outpatient clinic were selected using a simple random sampling method. In order to make the evaluation, the sociodemographic form and Diabetes Self-Management Scale has been used. Potential risk factors associated with the presence of diabetic foot were examined using multivariate logistic regression analysis. A significance level of <i>p</i> < 0.05 was considered statistically significant.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The mean age of the patients was 60.35 years and 45.1% (60) of them were female. According to the results of the multivariate logistic regression analysis, having more than 12 years of education, receiving diabetes education, and having higher Diabetes Self-Management Scale total scores negatively predicted the presence of diabetic foot. On the other hand, the duration of diabetes, systolic blood pressure, and HbA1c levels positively predicted the presence of diabetic foot.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Effective diabetes self-management plays a crucial role in improving diabetes complications. Care should be taken regarding diabetic foot in patients who have difficulties in effective diabetes self-management, as well as those with high systolic blood pressure, high HbA1c levels, shorter total education duration, and longer duration of diabetes.</p>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139954333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-17DOI: 10.1007/s13410-024-01321-9
Abstract
Objective
To assess the efficacy and safety of fixed-dose combinations (FDC) of triple-drug dapagliflozin, sitagliptin, and metformin (DSM) compared with FDC of two-drug sitagliptin and metformin (SM), in Indian adult patients with type 2 diabetes (T2D).
Methods
A multicentric, randomized, double-blind, active-controlled, Phase 3 study (CTRI/2021/10/037461) was conducted on 274 Indian adult patients with T2D. Patients were randomized (1:1) to receive either an FDC of triple-drug (n = 137) dapagliflozin propanediol 10 mg, sitagliptin phosphate 100 mg, and metformin hydrochloride 1000 mg extended-release (DSM) or FDC of two-drug (n = 137) sitagliptin phosphate 100 mg and metformin hydrochloride 1000 mg sustained-release (SM), for 16 weeks. The primary endpoint was a change in HbA1c, while the secondary endpoints were changes in fasting plasma glucose (FPG), postprandial glucose (PPG), body weight, and safety.
Results
Both DSM and SM FDCs reduced HbA1c significantly (-1.45% and -1.00%, respectively, both p < 0.0001), however, HbA1c lowering was superior with DSM (∆ -0.45%; p = 0.0005) compared to SM, at week 16. Similarly, both DSM and SM FDCs reduced FPG and PPG significantly, however, FPG (∆ -12.4 mg/dl; p = 0.003) and PPG reduction (∆ -18.45 mg/dl; p = 0.01) were significantly superior to DSM compared to SM, respectively. No significant reduction in body weight was observed between the two arms. Both FDCs were well tolerated.
Conclusion
FDC of DSM was superior to SM in reducing HbA1c, FPG, and PPG in Indian adults with T2D. Both triple and dual FDCs had optimal safety profiles.
{"title":"A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial","authors":"","doi":"10.1007/s13410-024-01321-9","DOIUrl":"https://doi.org/10.1007/s13410-024-01321-9","url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Objective</h3> <p>To assess the efficacy and safety of fixed-dose combinations (FDC) of triple-drug dapagliflozin, sitagliptin, and metformin (DSM) compared with FDC of two-drug sitagliptin and metformin (SM), in Indian adult patients with type 2 diabetes (T2D).</p> </span> <span> <h3>Methods</h3> <p>A multicentric, randomized, double-blind, active-controlled, Phase 3 study (CTRI/2021/10/037461) was conducted on 274 Indian adult patients with T2D. Patients were randomized (1:1) to receive either an FDC of triple-drug (<em>n</em> = 137) dapagliflozin propanediol 10 mg, sitagliptin phosphate 100 mg, and metformin hydrochloride 1000 mg extended-release (DSM) or FDC of two-drug (<em>n</em> = 137) sitagliptin phosphate 100 mg and metformin hydrochloride 1000 mg sustained-release (SM), for 16 weeks. The primary endpoint was a change in HbA1c, while the secondary endpoints were changes in fasting plasma glucose (FPG), postprandial glucose (PPG), body weight, and safety.</p> </span> <span> <h3>Results</h3> <p>Both DSM and SM FDCs reduced HbA1c significantly (-1.45% and -1.00%, respectively, both <em>p</em> < 0.0001), however, HbA1c lowering was superior with DSM (∆ -0.45%; <em>p</em> = 0.0005) compared to SM, at week 16. Similarly, both DSM and SM FDCs reduced FPG and PPG significantly, however, FPG (∆ -12.4 mg/dl; <em>p</em> = 0.003) and PPG reduction (∆ -18.45 mg/dl; <em>p</em> = 0.01) were significantly superior to DSM compared to SM, respectively. No significant reduction in body weight was observed between the two arms. Both FDCs were well tolerated.</p> </span> <span> <h3>Conclusion</h3> <p>FDC of DSM was superior to SM in reducing HbA1c, FPG, and PPG in Indian adults with T2D. Both triple and dual FDCs had optimal safety profiles.</p> </span>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139752192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Diabetes patients often suffer from diabetes keratopathy in the course of their illness. The examination of corneal endothelium in proliferative diabetic retinopathy (PDR) patients has important clinical significance. Here, we investigated the effect of PDR on corneal endothelial parameters.
Objective
To analyze the associations between corneal endothelial cell parameters and proliferative diabetic retinopathy (PDR).
Methods
We analyzed endothelial cell density (ECD), coefficient of variation in cell size (CV), hexagonality, and neutrophil/lymphocyte ratio (NLR) in patients with PDR and compared them with age-matched controls. The influences of duration of diabetes mellitus and level of glycosylated hemoglobin (HbA1c) were also analyzed.
Results
The study group included 106 eyes of 106 PDR patients and 85 eyes of 85 control subjects. Significant differences were found in ECD (2,436.11 ± 222.08 cells/mm2 in PDR, 2527.16 ± 191.64 cells/mm2 in controls; p < 0.05), CV (41.32 ± 7.40 in PDR, 37.71 ± 5.08 in controls; p < 0.05), Hex (50.07 ± 5.32 in PDR patients, 53.29 ± 5.73 in controls; p < 0.05), and NLR (2.94 ± 1.27 in PDR, 2.12 ± 0.56 in controls; p < 0.05). In the PDR group, ECD showed a decreasing trend as age increased (p trend < 0.05), and Spearman’s correlation indicated a significant positive correlation between NLR and macular thickness (p < 0.05).
Conclusions
PDR had deleterious effects on the corneal endothelium. PDR patients should undergo a rigorous corneal assessment to analyze the status of endothelial health, to identify the optimal treatment.
{"title":"Corneal endothelial morphology changes in patients with proliferative diabetic retinopathy","authors":"Xiaoli Yu, Xiaojuan Chen, Lele Li, Min Wang, Lidan Xue, Yue Zhou, Lili Huang","doi":"10.1007/s13410-024-01318-4","DOIUrl":"https://doi.org/10.1007/s13410-024-01318-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background </h3><p>Diabetes patients often suffer from diabetes keratopathy in the course of their illness. The examination of corneal endothelium in proliferative diabetic retinopathy (PDR) patients has important clinical significance. Here, we investigated the effect of PDR on corneal endothelial parameters.</p><h3 data-test=\"abstract-sub-heading\">Objective</h3><p>To analyze the associations between corneal endothelial cell parameters and proliferative diabetic retinopathy (PDR).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We analyzed endothelial cell density (ECD), coefficient of variation in cell size (CV), hexagonality, and neutrophil/lymphocyte ratio (NLR) in patients with PDR and compared them with age-matched controls. The influences of duration of diabetes mellitus and level of glycosylated hemoglobin (HbA1c) were also analyzed.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The study group included 106 eyes of 106 PDR patients and 85 eyes of 85 control subjects. Significant differences were found in ECD (2,436.11 ± 222.08 cells/mm<sup>2</sup> in PDR, 2527.16 ± 191.64 cells/mm<sup>2</sup> in controls; <i>p</i> < 0.05), CV (41.32 ± 7.40 in PDR, 37.71 ± 5.08 in controls; <i>p</i> < 0.05), Hex (50.07 ± 5.32 in PDR patients, 53.29 ± 5.73 in controls; <i>p</i> < 0.05), and NLR (2.94 ± 1.27 in PDR, 2.12 ± 0.56 in controls; <i>p</i> < 0.05). In the PDR group, ECD showed a decreasing trend as age increased (<i>p</i> trend < 0.05), and Spearman’s correlation indicated a significant positive correlation between NLR and macular thickness (<i>p</i> < 0.05).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>PDR had deleterious effects on the corneal endothelium. PDR patients should undergo a rigorous corneal assessment to analyze the status of endothelial health, to identify the optimal treatment.</p>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139752406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To determine the impacts of 12 weeks of aerobic, resistance, or combined training on FAM19A5, glucose homeostasis, body composition, and physical performance in obese men.
Methods
Fifty-eight obese men [age = 49 ± 6 years; body mass index (BMI) = 29 ± 2 kg m−2] were randomly assigned to aerobic training (n = 14), resistance training (n = 15), combined training (n = 15), and control (n = 14) groups. Interventions were three sessions per week for 12 weeks.
Results
FAM19A5 levels remained unaltered in all three intervention groups. However, insulin concentrations, triglyceride, HOMA-IR, VAI, TyG, and fat% declined in all three interventions, whereas VO2max increased. In addition, glucose levels, LAP, body weight, and BMI were reduced in aerobic and combined groups, while systolic blood pressure was reduced in resistance and combined programs. We also observed a significant reduction in low-density lipoprotein following only combined exercises and a significant increase in high-density lipoprotein after only aerobic exercises. There was a significant negative relationship between serum levels of FAM19A5 and HOMA-IR.
Conclusion
This is the first report to assess the influence of exercise interventions on circulating FAM19A5 levels in obese adults. Although FAM19A5 levels remained unchanged in all three interventions, our work provides information to support that aerobic, resistance, and combined regimens can be effective in improving HOMA-IR, triglyceride, systolic blood pressure, BMI, and aerobic performance in obese men. Additional studies with large sample size should be conducted to further clarify the underlying mechanisms.
{"title":"Impacts of a 12-week aerobic, resistance, and combined exercise training on serum FAM19A5, glucose homeostasis, and novel cardiovascular risk factors among adults with obesity","authors":"Ehsan Mir, Alireza Shamseddini, Najmeh Rahimi, Behzad Bazgir","doi":"10.1007/s13410-024-01315-7","DOIUrl":"https://doi.org/10.1007/s13410-024-01315-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>To determine the impacts of 12 weeks of aerobic, resistance, or combined training on FAM19A5, glucose homeostasis, body composition, and physical performance in obese men.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Fifty-eight obese men [age = 49 ± 6 years; body mass index (BMI) = 29 ± 2 kg m<sup>−2</sup>] were randomly assigned to aerobic training (<i>n</i> = 14), resistance training (<i>n</i> = 15), combined training (<i>n</i> = 15), and control (<i>n</i> = 14) groups. Interventions were three sessions per week for 12 weeks.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>FAM19A5 levels remained unaltered in all three intervention groups. However, insulin concentrations, triglyceride, HOMA-IR, VAI, TyG, and fat% declined in all three interventions, whereas VO<sub>2max</sub> increased. In addition, glucose levels, LAP, body weight, and BMI were reduced in aerobic and combined groups, while systolic blood pressure was reduced in resistance and combined programs. We also observed a significant reduction in low-density lipoprotein following only combined exercises and a significant increase in high-density lipoprotein after only aerobic exercises. There was a significant negative relationship between serum levels of FAM19A5 and HOMA-IR.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>This is the first report to assess the influence of exercise interventions on circulating FAM19A5 levels in obese adults. Although FAM19A5 levels remained unchanged in all three interventions, our work provides information to support that aerobic, resistance, and combined regimens can be effective in improving HOMA-IR, triglyceride, systolic blood pressure, BMI, and aerobic performance in obese men. Additional studies with large sample size should be conducted to further clarify the underlying mechanisms.</p>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139752410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}